Abstract: Provided is a sustained-release lipid pre-concentrate in the form of a lipid solution, including an unsaturated fatty acid having 14 to 20 carbon atoms (C14˜C20); a phospholipid; and ?-tocopherol acetate, wherein the sustained-release lipid pre-concentrate is free of diacyl glycerol and sorbitan unsaturated fatty acid ester; and forms a liquid crystal in an aqueous medium. Further provided is a sustained-release injectable pharmaceutical composition in the form of a lipid solution, including the pre-concentrate and a pharmacologically active substance, wherein the sustained-release injectable pharmaceutical composition is free of diacyl glycerol and sorbitan unsaturated fatty acid ester.

Abstract: In certain aspects, the disclosure relates to a nucleic acid molecule encoding a cytokine (e.g., IL-12) and one or more genetic switches encoding thanotransmission polypeptides (e.g., TRIF, Gasdermin E, or variants thereof). Vectors (e.g., engineered viruses, plasmids and transposons), cells and pharmaceutical compositions comprising one or more nucleic acid molecules encoding one or more thanotransmission polypeptides are also disclosed. Methods of promoting thanotransmission by a target cell, methods of promoting an immune response in a subject, and methods of treating cancer in a subject are further disclosed.

Abstract: In certain aspects, the disclosure relates to a nucleic acid molecule encoding one or more different thanotransmission polypeptides. Vectors (e.g., engineered viruses, plasmids and transposons), cells and pharmaceutical compositions comprising one or more nucleic acid molecules encoding one or more thanotransmission polypeptides are also disclosed. Methods of promoting thanotransmission by a target cell, methods of promoting an immune response in a subject, and methods of treating cancer in a subject are further disclosed.

Abstract: The present invention relates to a complex composition for preventing or treating hearing loss, including sarpogrelate and a Vaccinium myrtillus extract as active ingredients, wherein the complex composition has been confirmed to effectively inhibit hair cell death by reactive oxygen species generated by hydrogen peroxide, in a small dose, and exhibit an excellent protective effect on zebrafish auditory hair cells, and therefore, the complex composition can be effectively used as a drug or health food for preventing or treating hearing loss.

Abstract: The present application relates to creamer comprising vegetable lipids, casein, maltose, phosphates, and allulose.

Abstract: Disclosed are a drug evaluation method and apparatus. The drug evaluation method includes acquiring cell images in response to a drug to be evaluated, loading an image processing-based learning model trained so as to predict molar concentrations, outputting molar concentrations of cells corresponding to the cell images by applying the learning model to the acquired cell images, and calculating a drug evaluation value used to evaluate effects of the drug on the cells based on the molar concentrations of the cells corresponding to the cell images output through the learning model.

Abstract: An antibody or antigen-binding fragment thereof specifically binding to galectin 3-binding protein (LGALS3BP), and a use thereof, is described. The antibody or antigen-binding fragment thereof may comprise heavy chain CDRs and light chain CDRs of specific sequences. The antibody specifically binding to LGALS3BP has been found to inhibit cancer growth and metastasis in an animal model with cancer and may be effective for alleviating or treating cancer.

Abstract: The present invention relates to a novel cocrystal, a pharmaceutical composition comprising same and a preparation method therefor. By using the cocrystal of the present invention, cancers, inflammatory diseases, or viral infection diseases may be effectively prevented and/or treated.

Abstract: The present invention relates to a liquid crystalline structure-forming omega-3-fatty acid composition and, more specifically, provides an omega-3-fatty acid composition comprising: amphoteric lipids which form liquid crystalline structures when exposed to aqueous media such as gastrointestinal juice; omega-3 fatty acids or derivatives thereof; and a liquid crystalline structure-forming aid. The omega-3-fatty acid composition forms self-assembled lyotropic liquid crystals which are thermodynamically stable in structure, irrespective of digestion in the gastrointestinal tract, thereby promoting the solubilization and absorption rate of omega-3-fatty acids as well as providing preparations 30% or more smaller in size than conventional soft gel capsules of omega-3-fatty acid preparations. Thus, the composition can be taken with more ease by geriatric patients and the like and allows for provision of omega-3-fatty acid preparations increasing in in-vivo dissolution and absorption.

Abstract: The present invention relates to a composition comprising a bilberry extract as an active ingredient for preventing or treating sensorineural hearing impairment. The bilberry extract was found to exhibit effects of inhibiting the apoptosis of auditory cells in which sensorineural damage has been induced by neomycin and increasing a reduced number of hair cells in juvenile zebra fishes such that the composition comprising the bilberry extract as an active ingredient can be provided as a pharmaceutical composition and a health food for preventing or treating various hearing impairments induced by sensorineural damage.

Abstract: The present application relates to creamer comprising vegetable lipids, casein, maltose, phosphates, and allulose.

Abstract: Disclosed are a drug evaluation method and apparatus. The drug evaluation method includes acquiring cell images in response to a drug to be evaluated, loading an image processing-based learning model trained so as to predict molar concentrations, outputting molar concentrations of cells corresponding to the cell images by applying the learning model to the acquired cell images, and calculating a drug evaluation value used to evaluate effects of the drug on the cells based on the molar concentrations of the cells corresponding to the cell images output through the learning model.

Abstract: Provided is a sustained-release lipid pre-concentrate in the form of a lipid solution, including an unsaturated fatty acid having 14 to 20 carbon atoms (C14˜C20); a phospholipid; and ?-tocopherol acetate, wherein the sustained-release lipid pre-concentrate is free of diacyl glycerol and sorbitan unsaturated fatty acid ester; and forms a liquid crystal in an aqueous medium. Further provided is a sustained-release injectable pharmaceutical composition in the form of a lipid solution, including the pre-concentrate and a pharmacologically active substance, wherein the sustained-release injectable pharmaceutical composition is free of diacyl glycerol and sorbitan unsaturated fatty acid ester.

Abstract: The present application relates to an allulose-containing composition for promoting excretion of vegetable lipids from the body and a food comprising the composition of the present application and vegetable lipids.

Abstract: Provided is a composition for preventing, improving or treating obesity, which includes a Platycodon grandiflorum extract as an active ingredient and a method for preparing the extract with an improved anti-obesity effect. The extract shows an effect of inhibiting increases in body weight and fat mass caused by a high-fat diet for normalization, an increase in fasting blood glucose and a decrease in energy expenditure in a diet-induced obesity mouse model. Further, compared to an extract prepared by a conventional extraction method, the Platycodon grandiflorum extract shows a more excellent effect of inhibiting increases in body weight and fat mass, fasting blood glucose, and blood lipid and adipokine contents in experiments, resulting in an excellent anti-obesity effect. Therefore, the Platycodon grandiflorum extract prepared is expected to be useful for preventing obesity and treating obesity-related complications that can be caused by an increase in fat mass as well as obesity.

Abstract: Provided is a detection method of a detection device. The detection device detects at least one object from an image by using depth information about the image obtained by a camera. The detection device identifies whether said at least one object is a person through three-dimensional (3D) head model matching, which matches a head candidate area of said at least one object with a 3D head model. The detection device calculates a feature for detection of a situation by using said at least one object when it is identified that said at least one object is the person.

Abstract: The present invention relates to a method for the detection of a protein including a histidine-tag using immunochromatography. The detection method of the present invention uses immunochromatography using the polymer particle fixed with the histidine-tag, wherein a histidine-tag specific antibody alone is used to detect a histidine-tag conjugated protein (recombinant protein) quickly without using a target protein specific antibody. This method is also efficient in detecting and quantifying the histidine-tagged protein included in the sample without using an additional apparatus but quickly and accurately.